Sarepta

3 Biotech Stocks With Potential

3 Biotech Stocks With Potential

Seeking Alpha

Sarepta's Meaningless Q1 Results

Sarepta's Meaningless Q1 Results

Motley Fool

[video]3 Biggest Biotech Crashes in April

[video]3 Biggest Biotech Crashes in April

Motley Fool

Sarepta Therapeutics: Irrational Exuberance

Sarepta Therapeutics: Irrational Exuberance

Seeking Alpha

Quickly Approaching Biopharma Catalyst Events

Quickly Approaching Biopharma Catalyst Events

Seeking Alpha

FDA Says, "Call Me Maybe"

FDA Says, "Call Me Maybe"

Motley Fool

2 Views on Sarepta's FDA News

2 Views on Sarepta's FDA News

Motley Fool

Sarepta tumbles after FDA requests more data on drug

Sarepta tumbles after FDA requests more data on drug

The Fly on the Wall

Sarepta Fans: A Single Data Slide Raises Questions About Glaxo's DMD Drug

Sarepta Fans: A Single Data Slide Raises Questions About Glaxo's DMD Drug

TheStreet.com